All times are listed in CEST (Central European Summer Time)

Found 2 Presentations For Request "1670O"

Proffered Paper - SARS-CoV-2 and cancer 1 Proffered Paper session

1670O - Prospective data of first 1,797 hospitalised patients with cancer and COVID-19 derived from the COVID-19 Clinical Information Network and international Severe Acute Respiratory and emerging Infections Consortium, WHO Coronavirus Clinical Characterisation Consortium

Presentation Number
1670O
Lecture Time
15:21 - 15:33
Speakers
  • Carlo Palmieri (Liverpool, United Kingdom)
Room
Channel 3
Date
19.09.2020
Time
14:25 - 16:05

Abstract

Background

The SARS-CoV-2 pandemic in the UK triggered a national characterisation protocol and information on co-morbidities including malignant neoplasm is recorded. A lack of prospective data regarding cancer patients with COVID-19 hampers the development of an evidence based approach in this population. The Clinical Characterisation Protocol-CANCER-UK is a UK multi-disciplinary project aimed at characterising the presentation and course of COVID-19 in cancer patients with the aim of informing practice.

Methods

The international Severe Acute Respiratory and emerging Infections Consortium (ISARIC)-4C COVID-19 Clinical Information Network (CO-CIN) collects data on hospital inpatients with proven/high likelihood of COVID-19. Data was collected in 166 UK sites using a questionnaire adopted by the WHO. Data on patients with malignant neoplasm was extracted from the main dataset. We chose a priori to restrict any analysis of outcome to patients who were admitted more than 14 days before data extraction (13th May 2020).

Results

As of 13th May 2020 1797 of 16160 participants had malignant neoplasm (8.6% of all cases). Age<50 62 (3.5%), 50-60 378 (21%), 70-79 558 (31%), 80+ 1002 (42%). Male 1147 (64%); Female 645 (36%). Commonest comorbidities chromic pulmonary disease (22%), chronic kidney disease (21%), uncomplicated diabetes (19%) and dementia (14%). Outcomes 35% discharged alive, 30% care ongoing & 35% died. Admiited to ICU: 150 cases (25% discharged alive,31% care ongoing & 45% died). Receiving invasive ventiation: 67 cases (18% discharged alive, 25% care ongoing:25% & 57% died). HR mortality for malignancy (adjusted for age, sex, other comorbidity): 1.13 (1.02-1.24, p=0.017). Data on presentation will be presented.

Conclusions

Europe’s largest prospective COVID-19 dataset demonstrates that cancer is independently associated with mortality in patients admitted with COVID-19. Data collection is on-going and updated data will be presented including a comparison of cancer vs. non-cancer cohort with regard to presentation, comorbidity and otucomes.

Clinical trial identification

ISRCTN66726260.

Editorial acknowledgement

No editorial assistance was received.

Legal entity responsible for the study

and international Severe Acute Respiratory and emerging Infections Consortium (ISARIC) WHO Coronavirus Clinical Characterisation Consortium (ISARIC4C).

Funding

UK Research and Innovation, Medical Research Council and Department for Health and Social Care.

Disclosure

All authors have declared no conflicts of interest.

Collapse
Proffered Paper - SARS-CoV-2 and cancer 1 Proffered Paper session

Invited Discussant LBA71 and 1670O

Lecture Time
15:33 - 15:43
Speakers
  • Benjamin Solomon (Melbourne, VIC, Australia)
Room
Channel 3
Date
19.09.2020
Time
14:25 - 16:05